Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Investig Drugs. 2006 Feb;7(2):186-90.Links

StreptAvax (ID Biomedical).

McMillan D.

The Queensland Institute of Medical Research, Bacterial Pathogenesis Laboratory, Brisbane, Australia. David.McMillan@qimr.edu.au

ID Biomedical, under license from the University of Tennessee, is developing StreptAvax, a potential subunit vaccine against group A streptococcal infection. By January 2005, analysis of data from phase II clinical trials conducted in adults was completed. Pediatric trials are not expected to begin before 2007.

PMID: 16499290 [PubMed - indexed for MEDLINE]

Recent Activity